These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. Beaino W; Anderson CJ J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Beaino W; Nedrow JR; Anderson CJ Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487 [TBL] [Abstract][Full Text] [Related]
9. Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide. Guo H; Yang J; Gallazzi F; Prossnitz ER; Sklar LA; Miao Y Bioconjug Chem; 2009 Nov; 20(11):2162-8. PubMed ID: 19817405 [TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche. Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586 [TBL] [Abstract][Full Text] [Related]
11. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors. Jiang M; Ferdani R; Shokeen M; Anderson CJ Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977 [TBL] [Abstract][Full Text] [Related]
12. Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma. Pun MD; Gallazzi F; Ho KV; Watkinson L; Carmack TL; Iweha E; Li L; Anderson CJ Mol Pharm; 2024 Jun; 21(6):2960-2969. PubMed ID: 38680059 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of an Anti-HER2 Nanobody Labeled with Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411 [TBL] [Abstract][Full Text] [Related]
15. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486 [TBL] [Abstract][Full Text] [Related]
16. PET Imaging of VLA-4 in a New BRAF Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528 [TBL] [Abstract][Full Text] [Related]
18. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713 [TBL] [Abstract][Full Text] [Related]
19. The in vivo fate of Kruijff RM; Raavé R; Kip A; Molkenboer-Kuenen J; Morgenstern A; Bruchertseifer F; Heskamp S; Denkova AG Sci Rep; 2019 Aug; 9(1):11671. PubMed ID: 31406320 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]